The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study

International Clinical Psychopharmacology · Published 2025-12-10 · DOI 10.1097/yic.0000000000000609

Authors being retrieved — see the publisher record. https://doi.org/10.1097/yic.0000000000000609

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial · International Clinical Psychopharmacology · 2025 · Same journal
Unspoken needs: an essential perspective in the treatment of schizophrenia · International Clinical Psychopharmacology · 2026 · Same journal
When antidepressants meet the gut microbiota: implications and challenges · International Clinical Psychopharmacology · 2024 · Same journal
Innovations and challenges in antipsychotic treatments and external modulating factors · International Clinical Psychopharmacology · 2025 · Same journal
Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study · International Clinical Psychopharmacology · 2025 · Same journal
Risperidone as an adjuvant treatment for obsessive-compulsive symptoms in patients with bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial · International Clinical Psychopharmacology · 2025 · Same journal
Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD) · International Clinical Psychopharmacology · 2026 · Same journal
Addressing the challenge of treatment adherence in major depressive disorder in different settings · International Clinical Psychopharmacology · 2026 · Same journal
Efficacy and safety of adjunctive therapy with lumateperone in major depressive disorder: a randomized-, double-blind, placebo-controlled clinical trial · International Clinical Psychopharmacology · 2025 · Same journal
Not all antipsychotic polypharmacy is the same · International Clinical Psychopharmacology · 2026 · Same journal